1. Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice
    Stephan Bartels et al, 2017, The Journal of Molecular Diagnostics CrossRef
  2. Association of Omics Features with Histopathology Patterns in Lung Adenocarcinoma
    Kun-Hsing Yu et al, 2017, Cell Systems CrossRef
  3. BRAF V600Q-mutated lung adenocarcinoma with duodenal metastasis and extreme leukocytosis
    Ayman Qasrawi et al, 2017, WJCO CrossRef
  4. null
    Byungkyu Park et al, 2018 CrossRef
  5. Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma
    Sun Min Lim et al, 2019, Lung Cancer CrossRef
  6. Complete and Durable Response to Combined Chemo/Radiation Therapy in EGFR Wild-Type Lung Adenocarcinoma with Diffuse Brain Metastases.
    Valli De re, 0 CrossRef
  7. Impact of KRAS Mutation Subtype and Concurrent Pathogenic Mutations on Non-Small Cell Lung Cancer Outcomes
    Jacqueline V. Aredo et al, 2019, Lung Cancer CrossRef
  8. Functional screens identify coordinators of RNA molecule birth, life, and death as targetable cancer vulnerabilities
    Christian J Braun et al, 2019, Current Opinion in Genetics & Development CrossRef
  9. p53/miR‐30a‐5p/ SOX4 feedback loop mediates cellular proliferation, apoptosis, and migration of non‐small‐cell lung cancer
    Xiaowei Quan et al, 2019, J Cell Physiol CrossRef
  10. Mechanisms of Compound Kushen Injection for the Treatment of Lung Cancer Based on Network Pharmacology
    Ziqi Meng et al, 2019, Evidence-Based Complementary and Alternative Medicine CrossRef
  11. Clinical characteristics and survival in non-small cell lung cancer patients by smoking history: a population-based cohort study
    Lukas Löfling et al, 2019, Acta Oncologica CrossRef
  12. Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital
    null Simarro et al, 2019, Cancers CrossRef
  13. Prognostic factors of acinar- or papillary-predominant adenocarcinoma of the lung
    Moonsik Kim et al, 2019, Lung Cancer CrossRef
  14. Harnessing the vulnerabilities of p53 mutants in lung cancer – Focusing on the proteasome: a new trick for an old foe?
    Eziafa I. Oduah et al, 2020, Cancer Biology & Therapy CrossRef
  15. Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
    Matteo Canale et al, 2020, JCM CrossRef
  16. Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer
    Yudong Wang et al, 2018, Oncotarget CrossRef
  17. Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup
    Elena Ciabatti et al, 2017, Oncotarget CrossRef
  18. EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models
    Sebastiao N. Martins-Filho et al, 2020, Lung Cancer CrossRef
  19. Incorporating deep learning and multi-omics autoencoding for analysis of lung adenocarcinoma prognostication
    Tzong-Yi Lee et al, 2020, Computational Biology and Chemistry CrossRef
  20. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC
    Julia Roeper et al, 2020, Oncotarget CrossRef
  21. Sex-Specific Regulation of Gene Expression Networks by Surfactant Protein A (SP-A) Variants in Alveolar Macrophages in Response to Klebsiella pneumoniae
    Nithyananda Thorenoor et al, 2020, Front. Immunol. CrossRef
  22. Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer
    Yutao Liu et al, 2019, Oncol Lett CrossRef
  23. Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer
    Vito Carlo Alberto Caponio et al, 2020, Br J Cancer CrossRef
  24. Impact of genetic alterations on outcomes of patients with stage I nonsmall cell lung cancer: An analysis of the cancer genome atlas data
    Song Xu et al, 2020, Cancer Med CrossRef
  25. Toxoplasma GRA16 Inhibits NF-κB Activation through PP2A-B55 Upregulation in Non-Small-Cell Lung Carcinoma Cells
    Seung-Hwan Seo et al, 2020, IJMS CrossRef
  26. Triangular Relationship between p53, Autophagy, and Chemotherapy Resistance
    Jingwen Xu et al, 2020, IJMS CrossRef
  27. p53-Suppressed Oncogene TET1 Prevents Cellular Aging in Lung Cancer.
    Piotr T Filipczak et al, 2019, Cancer Res CrossRef
  28. Uncovering the Anti-Lung-Cancer Mechanisms of the Herbal Drug FDY2004 by Network Pharmacology
    Ho-Sung Lee et al, 2021, Evidence-Based Complementary and Alternative Medicine CrossRef
  29. Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Lijuan Zhang et al, 2021, Scand J Immunol CrossRef
  30. Calling Attention to the Role of Race-Driven Societal Determinants of Health on Aggressive Tumor Biology: A Focus on Black Americans
    Kimlin T. Ashing et al, 2021, JCO Oncology Practice CrossRef
  31. The Association between Polluted Neighborhoods and TP53-Mutated Non–Small Cell Lung Cancer
    Loretta Erhunmwunsee et al, 2021, Cancer Epidemiol Biomarkers Prev CrossRef
  32. Genomic and evolutionary classification of lung cancer in never smokers
    Tongwu Zhang et al, 2021, Nat Genet CrossRef
  33. MicroRNA-324-5p–CUEDC2 Axis Mediates Gain-of-Function Mutant p53-Driven Cancer Stemness
    Dishari Ghatak et al, 2021, Mol Cancer Res CrossRef
  34. Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC
    Mohamed Mahde Saleh et al, 2021, Journal of Thoracic Oncology CrossRef
  35. Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
    Maja Šutić et al, 2021, JPM CrossRef
  36. Mutational landscape in squamous cell carcinoma of the nail unit
    Emi Dika et al, 2022, Experimental Dermatology CrossRef
  37. RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC
    Lei Duan et al, 2022, Sci Rep CrossRef
  38. Updated Prognostic Factors in Localized NSCLC
    Simon Garinet et al, 2022, Cancers CrossRef
  39. Novel protein contact points among TP53 and minichromosome maintenance complex proteins 2, 3, and 5
    Stephanie Schaefer‐Ramadan et al, 2022, Cancer Medicine CrossRef
  40. Mechanisms of Resistance to first-line Osimertinib in Hispanic patients with EGFR mutant non-small cell lung cancer (FRESTON-CLICaP)
    Andrés F. Cardona et al, 2022, Clinical Lung Cancer CrossRef
  41. Establishing an 8‐gene immune prognostic model based on TP53 status for lung adenocarcinoma
    Guodong Wu et al, 2022, Clinical Laboratory Analysis CrossRef
  42. A Real-World Systematic Analysis of Driver Mutations’ Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting
    Irene Terrenato et al, 2022, Cancers CrossRef
  43. Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
    Matteo Canale et al, 2022, Translational Oncology CrossRef
  44. The Lung Alveolar Cell (LAC) miRNome and Gene Expression Profile of the SP-A-KO Mice After Infection With and Without Rescue With Human Surfactant Protein-A2 (1A0)
    Nithyananda Thorenoor et al, 2022, Front. Immunol. CrossRef
  45. Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment
    Yingjia Sun et al, 2022, JCM CrossRef
  46. Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes
    Alessandro Di Federico et al, 2022, Cancers CrossRef
  47. Deregulated transcription factors and poor clinical outcomes in cancer patients
    Yiwei Li et al, 2022, Seminars in Cancer Biology CrossRef
  48. Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
    Alissa J. Cooper et al, 2022, JTO Clinical and Research Reports CrossRef
  49. Genomic alterations predictive of poor clinical outcomes in pan-cancer
    Crystal S. Seldon et al, 2022, Oncotarget CrossRef
  50. Opposing Roles of IGFBP-3 and Heparanase in Regulating A549 Lung Cancer Cell Survival
    Hind Al Khashali et al, 2022, Cells CrossRef
  51. Genetic network and gene set enrichment analyses identify MND1 as potential diagnostic and therapeutic target gene for lung adenocarcinoma
    Jinying Wei et al, 2021, Sci Rep CrossRef
  52. Integrative bioinformatic analysis of p53 and pathway alterations in two different lung cancer subtypes
    Yun Zhang et al, 2023, Biochemistry and Biophysics Reports CrossRef
  53. Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation
    Kai Shang et al, 2022, BMC Cancer CrossRef
  54. Metabolic targeting, immunotherapy and radiation in locally advanced non-small cell lung cancer: Where do we go from here?
    Annika Dhawan et al, 2022, Front. Oncol. CrossRef
  55. Phosphorylation of IGFBP-3 by Casein Kinase 2 Blocks Its Interaction with Hyaluronan, Enabling HA-CD44 Signaling Leading to Increased NSCLC Cell Survival and Cisplatin Resistance
    Kai-ling Coleman et al, 2023, Cells CrossRef
  56. Biomarkers of response to immunotherapy in early stage non-small cell lung cancer
    Matthieu Roulleaux Dugage et al, 2023, European Journal of Cancer CrossRef
  57. Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
    Haiyan Sun et al, 2023, BMC Cancer CrossRef